Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Theodore P. Abraham et al.|The Lancet|2020Cited by 1.2k
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysisMarco Valgimigli, Pieter C. Smits, Enrico Frigoli et al.|European Heart Journal|2022Cited by 78